Real‐world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis

Abstract

OBV/PTV/r+DSV+RBV proved to be highly efficient in our population of cirrhotics with a 96.6% SVR. Serious adverse events related to therapy were reported in 61/2070(2.9%), most of them liver decompensation (1.9%), related to hepatic dysfunction, and lower platelet count.

Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild‐moderate fibrosis: Results from a real‐world cohort

“…10 Beyond clinical trials, numerous studies have evaluated the PTV/r/OBV + DSV combination administered for 12 weeks in clinical practice, all of them including a great proportion of patients with cirrhosis. [11][12][13][14][15][16][17] As a whole, these studies have consistently shown SVR12 rates higher than 95% in all subgroups of patients, confirming data obtained from pivotal clinical trials. A recent meta-analysis evaluating more than 5000 patients from 20 real-world cohorts of 12 different countries has shown SVR12 rates in genotype 1b-infected patients of 98%, with only 2.5% of drug discontinuations and 3.12% of SAEs.…”

Risk of hepatitis B virus reactivation in hepatitis B virus + hepatitis C virus‐co‐infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r + dasabuvir + ribavirin

“…We previously reported a very high rate of HCV SVR in our large cohort of 2070 patients: 96.6% in intention to treat and the SVR reached even 100% in co-infected patients. 22 Even though we reported 2.9% rate of serious adverse events leading to discontinuation of therapy, most of them with liver decompensations (rate 1.9%), we did not have such events in HBV-co-infected patients. 0%-30%, HBV-associated hepatitis; and 0%-30%, necessitating anti-HBV treatment.…”

“…DAA therapy has high success rate (more than 90%) and fewer side effects than the interferon-based regimens. [22][23][24][25][26] The current guidelines for coinfected patients with HCV and HBV recommend that when HCV is replicative, the patient should receive the standard treatment for HCV infection. 27,28 A major concern in the treatment of HBV-HCV co-infection is a "flare-up" of hepatitis due to the risk of HBV reactivation during or after HCV clearance that may increase the risk of liver damage.…”

Treatment of hepatitis C: Results in real life

“…In the German cohort, analysis of response across subgroups showed consistently high SVR rates: 95% in patients with cirrhosis (n = 123/129), 100% in those with moderate to severe renal impairment (n = 34/34) and 96% in subgroups that are usually excluded from clinical trials (including patients ≥70 years old [n = 64/67] and prior failures to protease inhibitor treatment [n = 46/48]). The results from a Romanian cohort also confirmed this, reporting an SVR of 96.6% in patients with genotype 1b and cirrhosis receiving ombitasvir/paritaprevir/ritonavir plus dasabuvir, administered with ribavirin …”